Cytotoxic T-lymphocyte protein 4
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein heterocomplex Heteromer Protein × 3 PDB declaration: trimeric(3) Consistent with protein copy count | Chain C; UniProt 36–161 | Not recorded | heavy chain of Fab × 1 light chain of Fab × 1 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION, SITTING DROP;285 K;PEG8000 10%, 0.1M Na Citrate 0.1M (NH4)2SO4 | Resolution 2.14 Å R-free 0.217 |
| 2 | Protein heterocomplex Heteromer Protein × 3 PDB declaration: trimeric(3) Consistent with protein copy count | Chain c; UniProt 36–161 | Not recorded | heavy chain of Fab × 1 light chain of Fab × 1 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION, SITTING DROP;285 K;PEG8000 10%, 0.1M Na Citrate 0.1M (NH4)2SO4 | Resolution 2.14 Å R-free 0.217 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 7ELX | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1AH1 CTLA-4, NMR, 20 STRUCTURES Deposited 1997-04-11 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
37–161(125 aa)
Fragment:EXTRACELLULAR N-TERMINAL IMMUNOGLOBULIN V-LIKE
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7;303 K
|
Resolution not provided |
| 1H6E MU2 ADAPTIN SUBUNIT (AP50) OF AP2 ADAPTOR (SECOND DOMAIN), COMPLEXED WITH CTLA-4 INTERNALIZATION PEPTIDE TTGVYVKMPPT Deposited 2001-06-12 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain P
197–207(11 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;HANGING DROPS CONTAINING A 1:1 MIXTURE OF COMPLEX SOLUTION 6MG/ML PROTEIN AND 1MM 11MER PEPTIDE SOLUTION IN 20MM HEPES PH7.5, 1MM DTT AND RESERVOIR BUFFER 1.4-2.4M SODIUM CHLORIDE, 0.1M MES PH6.2-7.0, 0.4M NA/K PHOSPHATE, 15% GLYCEROL, pH 7.00
|
Resolution 3.60 Å R-free 0.317 |
| 1I85 CRYSTAL STRUCTURE OF THE CTLA-4/B7-2 COMPLEX Deposited 2001-03-12 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain C
36–161(126 aa)
Fragment:EXTRACELLULAR DOMAIN
Chain D
36–161(126 aa)
Fragment:EXTRACELLULAR DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;PEG20K, HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 3.20 Å R-free 0.300 |
| 1I8L HUMAN B7-1/CTLA-4 CO-STIMULATORY COMPLEX Deposited 2001-03-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain C
36–161(126 aa)
Fragment:EXTRACELLULAR DOMAIN, RESIDUES 36-161
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 9 MAN alpha-D-mannopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.3;298 K;16% PEG 8000, 0.1M CACODYLATE, PH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 3.00 Å R-free 0.257 |
| 1I8L HUMAN B7-1/CTLA-4 CO-STIMULATORY COMPLEX Deposited 2001-03-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain D
36–161(126 aa)
Fragment:EXTRACELLULAR DOMAIN, RESIDUES 36-161
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 9 MAN alpha-D-mannopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.3;298 K;16% PEG 8000, 0.1M CACODYLATE, PH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 3.00 Å R-free 0.257 |
| 2X44 Structure of a strand-swapped dimeric form of CTLA-4 Deposited 2010-01-28 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain D
36–161(126 aa)
Fragment:RESIDUES 36-161
|
Mutation:YES | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5;0.02 M MAGNESIUM CHLORIDE, 0.1 M HEPES PH 7.5, 22 % W/V POLYACRYLIC ACID 5100 SODIUM SALT, 0.4 M NDSB-256 (OR 6 % 1,6-DIAMINOHEXANE).
|
Resolution 2.60 Å R-free 0.245 |
| 3BX7 Engineered Human Lipocalin 2 (LCN2) in Complex with the Extracellular Domain of Human CTLA-4 Deposited 2008-01-11 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain C
38–161(124 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.4;293.15 K;1.4 M Na-malonate, pH 8.4, VAPOR DIFFUSION, SITTING DROP, temperature 293.15K
|
Resolution 2.10 Å R-free 0.226 |
| 3OSK Crystal structure of human CTLA-4 apo homodimer Deposited 2010-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
36–161(126 aa)
Fragment:Extracellular domain, UNP residues 36-161
Chain B
36–161(126 aa)
Fragment:Extracellular domain, UNP residues 36-161
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;295 K;25% Polyethylene glycol 3350 (w/v), 100mM bis-Tris pH 5.5, 200mM ammonium acetate, VAPOR DIFFUSION, SITTING DROP, temperature 295K
|
Resolution 1.80 Å R-free 0.275 |
| 5GGV CTLA-4 in complex with tremelimumab Fab Deposited 2016-06-16 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain Y
36–161(126 aa)
Fragment:UNP residues 36-161
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M sodium citrate tribasic dihydrate, pH 5.6, 12% PEG4,000, 100 mM NaCl
|
Resolution 2.00 Å R-free 0.214 |
| 5TRU Structure of the first-in-class checkpoint inhibitor Ipilimumab bound to human CTLA-4 Deposited 2016-10-27 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain C
37–154(118 aa)
Fragment:UNP residues 37-154
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.5;291 K;0.1M ammonium sulfate, 0.1M Tris pH 7.5, 20% PEG 1500
|
Resolution 3.00 Å R-free 0.268 |
| 5TRU Structure of the first-in-class checkpoint inhibitor Ipilimumab bound to human CTLA-4 Deposited 2016-10-27 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain c
37–154(118 aa)
Fragment:UNP residues 37-154
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.5;291 K;0.1M ammonium sulfate, 0.1M Tris pH 7.5, 20% PEG 1500
|
Resolution 3.00 Å R-free 0.268 |
| 5XJ3 Complex structure of ipilimumab-scFv and CTLA-4 Deposited 2017-04-29 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 12 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain L
36–161(126 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 9;291 K;100 mM BICINE, 10% PEG 20000, 2% 1,4-Dioxane, pH 9.0.
|
Resolution 3.20 Å R-free 0.264 |
| 5XJ3 Complex structure of ipilimumab-scFv and CTLA-4 Deposited 2017-04-29 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain C
36–161(126 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 9;291 K;100 mM BICINE, 10% PEG 20000, 2% 1,4-Dioxane, pH 9.0.
|
Resolution 3.20 Å R-free 0.264 |
| 5XJ3 Complex structure of ipilimumab-scFv and CTLA-4 Deposited 2017-04-29 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 6 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain F
36–161(126 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 9;291 K;100 mM BICINE, 10% PEG 20000, 2% 1,4-Dioxane, pH 9.0.
|
Resolution 3.20 Å R-free 0.264 |
| 5XJ3 Complex structure of ipilimumab-scFv and CTLA-4 Deposited 2017-04-29 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 9 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain I
36–161(126 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 9;291 K;100 mM BICINE, 10% PEG 20000, 2% 1,4-Dioxane, pH 9.0.
|
Resolution 3.20 Å R-free 0.264 |
| 6RP8 Crystal Structure of Ipilimumab Fab complexed with CTLA-4 at 2.6A resolution Deposited 2019-05-14 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain c
37–154(118 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;PEG4000, pH6
|
Resolution 2.60 Å R-free 0.267 |
| 6RP8 Crystal Structure of Ipilimumab Fab complexed with CTLA-4 at 2.6A resolution Deposited 2019-05-14 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain C
37–154(118 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;PEG4000, pH6
|
Resolution 2.60 Å R-free 0.267 |
| 6RPJ A Non-blocking anti-CTLA-4 Nanobody complexed with CTLA-4 Deposited 2019-05-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
37–156(120 aa)
Chain G
37–156(120 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;PEG400
|
Resolution 3.25 Å R-free 0.262 |
| 6RPJ A Non-blocking anti-CTLA-4 Nanobody complexed with CTLA-4 Deposited 2019-05-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain C
37–156(120 aa)
Chain E
37–156(120 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;PEG400
|
Resolution 3.25 Å R-free 0.262 |
| 6RQM A blocking anti-CTLA-4 Nanobody (KN044) complexed with CTLA-4 Deposited 2019-05-16 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
37–161(125 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;PEG400,
|
Resolution 3.00 Å R-free 0.313 |
| 6XY2 Crystal structure of CTLA-4 complexed with the Fab of HL32 antibody Deposited 2020-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain A
38–160(123 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE;pH 6.5;293 K;1M Li2SO4, 1.5M NH4SO4, 0.1M Sodium citrate
|
Resolution 3.05 Å R-free 0.292 |
| 7CIO Molecular interactions of cytoplasmic region of CTLA-4 with SH2 domains of PI3-kinase Deposited 2020-07-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
199–206(8 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;293 K;0.2 M ammonium acetate, 0.1 M sodium acetate trihydrate pH 4.6, 30% PEG 4000
|
Resolution 1.10 Å R-free 0.179 |
| 7DV4 Crystal structure of anti-CTLA-4 VH domain in complex with human CTLA-4 Deposited 2021-01-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
36–153(118 aa)
Chain G
36–153(118 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;100 mM sodium citrate, 10% (w/v) PEG 6000, pH 5.0
|
Resolution 2.38 Å R-free 0.258 |
| 7DV4 Crystal structure of anti-CTLA-4 VH domain in complex with human CTLA-4 Deposited 2021-01-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain C
36–153(118 aa)
Chain E
36–153(118 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;100 mM sodium citrate, 10% (w/v) PEG 6000, pH 5.0
|
Resolution 2.38 Å R-free 0.258 |
| 7SU0 Crystal structure of an acidic pH-selective Ipilimumab variant Ipi.105 in complex with CTLA-4 Deposited 2021-11-15 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain C
36–153(118 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M ammonium citrate dibasic, 20% w/v PEG 1,000, pH 5.2
|
Resolution 2.41 Å R-free 0.264 |
| 7SU0 Crystal structure of an acidic pH-selective Ipilimumab variant Ipi.105 in complex with CTLA-4 Deposited 2021-11-15 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain D
36–153(118 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 FLC CITRATE ANION × 1 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M ammonium citrate dibasic, 20% w/v PEG 1,000, pH 5.2
|
Resolution 2.41 Å R-free 0.264 |
| 7SU1 Crystal structure of an acidic pH-selective Ipilimumab variant Ipi.106 in complex with CTLA-4 Deposited 2021-11-15 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain C
36–153(118 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M sodium citrate tribasic dehydrate, 22% PEG 3,350
|
Resolution 2.53 Å R-free 0.251 |
| 8GAB Crystal structure of CTLA-4 in complex with a high affinity CTLA-4 binder Deposited 2023-02-22 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
36–161(126 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;292 K;22% (w/v) PEG 3350 and 0.2 M KCl
|
Resolution 2.72 Å R-free 0.292 |
| 8GAB Crystal structure of CTLA-4 in complex with a high affinity CTLA-4 binder Deposited 2023-02-22 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain D
36–161(126 aa)
|
Not recorded | K POTASSIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;292 K;22% (w/v) PEG 3350 and 0.2 M KCl
|
Resolution 2.72 Å R-free 0.292 |
| 8HIT Crystal structure of anti-CTLA-4 humanized IgG1 MAb--JS007 in complex with human CTLA-4 Deposited 2022-11-21 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain C
35–154(120 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;100mM Tris, pH 8.5, 30% w/v PEG 4000
|
Resolution 3.20 Å R-free 0.298 |
| 9DQ3 Crystal structure of engineered Ipilimumab (mipi.4) Fab in complex with human CTLA-4 Deposited 2024-09-23 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain C
36–153(118 aa)
Fragment:Extracellular domain of human CTLA-4 with hexahistidine tag
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;300 K;0.18 M calcium acetate hydrate, 22.5% w/v PEG3350
|
Resolution 1.64 Å R-free 0.268 |
21 other PDB entries and 31 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | CTLA4_HUMAN |
| Isoform | — |
| PDB entities | 3 |
| Chains and sequence ranges | Author chain C; PDBConstruct 1–126; UniProt 36–161 Author chain c; PDBConstruct 1–126; UniProt 36–161 |